Tyme Technologies, Inc. (TYME): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYME Stock Price Chart Interactive Chart >
TYME Price/Volume Stats
|Current price||$1.14||52-week high||$4.99|
|Prev. close||$1.08||52-week low||$0.85|
|Day high||$1.14||Avg. volume||7,059,046|
|50-day MA||$1.09||Dividend yield||N/A|
|200-day MA||$1.51||Market Cap||196.32M|
Tyme Technologies, Inc. (TYME) Company Bio
Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.
Most Popular Stories View All
TYME Latest News Stream
|Loading, please wait...|
TYME Latest Social Stream
View Full TYME Social Stream
Latest TYME News From Around the Web
Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.
Every investor in Tyme Technologies, Inc. ( NASDAQ:TYME ) should be aware of the most powerful shareholder groups...
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBT
Good morning, investor!
Earnings results for Tyme Technologies , Analyst Opinion on Tyme Technologies , Earnings and Valuation of (NASDAQ:TYME), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Nothing seems to bother Tyme Technologies (NASDAQ:TYME) appeared first on .
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its fiscal first quarter ended June 30, 2021. Fiscal First Quarter 2022 Business and Recent Highlights: Completed strategic review and identified clinical priorities with a focus on metastatic hormone receptor positive, human epidermal growth factor receptor 2 ne
TYME Price Returns